Ellevest Inc’s Heron Therapeutics HRTX Stock Holding History

Ellevest Inc’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-79	Closed	–	–	1707
2022 Q2	$0	Buy	79 +72	+1,029%	+$289	﹤0.01%	1514
2022 Q1	$0	Buy	+7	New	+$51	﹤0.01%	1506

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ellevest Inc's HRTX Position: Q3 2022 in Review

Ellevest Inc sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 79 shares.

Ellevest Inc first reported a position in HRTX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

Ellevest Inc reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 79 Heron Therapeutics shares in Q3 2022.
Ellevest Inc first reported a position in Heron Therapeutics in Q1 2022 and held it in 2 quarters.
Ellevest Inc's Heron Therapeutics position peaked at $0 in Q2 2022.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.